NCT02876900View on ClinicalTrials.gov

Study to Assess Efficacy and Safety of HP3070 in Subjects Diagnosed With Schizophrenia.

PHASE3CompletedINTERVENTIONAL
Enrollment

617

Participants

Timeline

Start Date

August 31, 2016

Primary Completion Date

June 30, 2018

Study Completion Date

June 30, 2018

Conditions
Schizophrenia
Interventions
DRUG

Low Dose Asenapine maleate transdermal patch

The study will evaluate low dose Asenapine maleate transdermal patch

DRUG

High Dose Asenapine maleate transdermal patch

The study will evaluate high dose Asenapine maleate transdermal patch

DRUG

Placebo

The study will evaluate placebo transdermal patch.

Trial Locations (1)

07310

Noven Pharmaceuticals, Inc., Jersey City

Sponsors
All Listed Sponsors
lead

Noven Pharmaceuticals, Inc.

INDUSTRY